XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 12 - Segment Data - Operating Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Mar. 31, 2022
Revenues $ 58,749 $ 35,840 $ 109,202 $ 70,760  
Total revenues 58,749 35,840 109,202 70,760  
Gross profit (loss) 36,386 23,140 67,727 45,351  
Gross profit (loss) 36,386 23,140 67,727 45,351  
Operating expenses 32,391 18,939 68,326 38,027  
Operating income (loss) 3,995 4,201 (599) 7,324  
Nonoperating expense (income), net 611 (342) 1,429 1,363  
Earnings (loss) before income taxes 3,384 4,543 (2,028) 5,961  
Total inventories 28,039   28,039   $ 24,606
Operating Segments [Member]          
Revenues [1] 58,749 35,840 109,202 70,760  
Total revenues [1] 58,749 35,840 109,202 70,760  
Gross profit (loss) 36,404 23,215 67,762 45,447  
Gross profit (loss) 36,404 23,215 67,762 45,447  
Operating expenses 32,391 18,939 68,326 38,027  
Operating income (loss) 3,995 4,201 (599) 7,324  
Nonoperating expense (income), net 611 (342) 1,429 1,363  
Operating Segments [Member] | Clinical Genomics [Member]          
Revenues 18,435 0 32,940 0  
Total revenues 18,435 0 32,940 0  
Gross profit (loss) 10,641 0 18,490 0  
Gross profit (loss) 10,641 0 18,490 0  
Total inventories 12,600   12,600   11,802
Operating Segments [Member] | Sterilization and Disinfection Control [Member]          
Revenues 16,964 14,033 31,738 29,183  
Total revenues 16,964 14,033 31,738 29,183  
Gross profit (loss) 12,199 10,486 22,967 21,914  
Gross profit (loss) 12,199 10,486 22,967 21,914  
Total inventories 2,864   2,864   2,176
Operating Segments [Member] | Biopharmaceutical Development [Member]          
Revenues 12,144 10,555 23,111 19,432  
Total revenues 12,144 10,555 23,111 19,432  
Gross profit (loss) 7,557 6,601 14,634 11,293  
Gross profit (loss) 7,557 6,601 14,634 11,293  
Total inventories 5,214   5,214   4,495
Operating Segments [Member] | Calibration Solutions [Member]          
Revenues [2] 11,206 11,252 21,413 22,145  
Total revenues [2] 11,206 11,252 21,413 22,145  
Gross profit (loss) 6,007 6,128 11,671 12,240  
Gross profit (loss) 6,007 6,128 11,671 12,240  
Total inventories 7,361   7,361   $ 6,133
Corporate, Non-Segment [Member]          
Gross profit (loss) [3] (18) (75) (35) (96)  
Gross profit (loss) [3] $ (18) $ (75) $ (35) $ (96)  
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals
[2] Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021.
[3] Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other.